Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.

Authors: Geelen, Inge G.P.¹ (AUTHOR) i.geelen@erasmusmc.nl, Gullaksen, Stein-Erik^2,3 (AUTHOR), Ilander, Mette M.⁴ (AUTHOR), Olssen-Strömberg, Ulla⁵ (AUTHOR), Mustjoki, Satu^4,6,7 (AUTHOR), Richter, Johan⁸ (AUTHOR), Blijlevens, Nicole M.A.⁹ (AUTHOR), Smit, Willem M.¹⁰ (AUTHOR), Gjertsen, Bjorn T.^2,3 (AUTHOR), Gedde-Dahl, Tobias¹¹ (AUTHOR), Markevärn, Berit¹² (AUTHOR), Koppes, Malika M.A.¹³ (AUTHOR), Westerweel, Peter E.¹ (AUTHOR), Hjorth-Hansen, Henrik^14,15 (AUTHOR), Janssen, Jeroen J.W.M.¹³ (AUTHOR)

Source: Annals of Hematology. Jun2023, Vol. 102 Issue 6, p1395-1408. 14p.

Subject Terms: *CHRONIC myeloid leukemia, *NILOTINIB, *IMATINIB

Influence of WHO versus ELN advanced phase chronic myeloid leukemia definitions on overall survival.

Authors: Geelen, Inge G.P.¹, Thielen, Noortje^2,3, Janssen, Jeroen J.W.M.², Levin, Mark‐David¹, Hoogendoorn, Mels⁴, Visser, Otto⁵, Cornelissen, Jan J.⁶, Westerweel, Peter E.¹ p.e.westerweel@asz.nl

Source: European Journal of Haematology. Oct2017, Vol. 99 Issue 4, p381-382. 2p.

Subject Terms: *CHRONIC myeloid leukemia, *HEALTH outcome assessment, *PATIENTS

CML Treatment in Dutch Hospitals with Low Patient Volumes Is Associated with a Substandard Quality of Molecular Response Monitoring

Authors: Geelen, Inge G.P. ^*, Thielen, Noortje ^*, Janssen, Jeroen J.W.M., Roosma, Tanja ^*, Visser, Otto, Cornelissen, Jan J., Westerweel, Peter E. ^*

Source: In Blood 2 December 2016 128(22):1913-1913